Affinage

DEPDC1B

DEP domain-containing protein 1B · UniProt Q8WUY9

Round 2 corrected
Length
529 aa
Mass
61.8 kDa
Annotated
2026-04-28
95 papers in source corpus 23 papers cited in narrative 23 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DEPDC1B is a DEP- and RhoGAP-domain-containing cell-cycle-regulated protein that coordinates focal adhesion dynamics with mitotic entry and promotes cell migration through Rho-family GTPase signaling. It accumulates in G2 phase and competes with RhoA for binding to the focal adhesion phosphatase PTPRF, thereby driving focal adhesion dismantling required for mitotic rounding (PMID:25458010). DEPDC1B functions as a Rac1 activator, binding Rac1 directly and stimulating downstream Rac1–PAK1–LIMK1–cofilin1 and Rac1–ERK signaling cascades that promote cell migration, invasion, and epithelial–mesenchymal transition across multiple cancer types (PMID:25091805, PMID:32110046, PMID:33135357). In addition to its GTPase-regulatory roles, DEPDC1B stabilizes β-catenin by recruiting the deubiquitinase USP5 and stabilizes SCUBE3 by sequestering the ubiquitin ligase subunit CDC16, linking it to Wnt/β-catenin signaling and metastatic angiogenesis (PMID:37642235, PMID:35088579).

Mechanistic history

Synthesis pass · year-by-year structured walk · 7 steps
  1. 2014 High

    The core cell-biological function of DEPDC1B was established: it accumulates in G2 and acts as a de-adhesion checkpoint by competing with RhoA for PTPRF binding, thereby coupling focal adhesion dismantling to mitotic entry — answering how cells coordinate adhesion loss with cell division.

    Evidence Reciprocal Co-IP, competition binding assays, siRNA/live-cell imaging, and zebrafish in vivo genetics

    PMID:25458010

    Open questions at the time
    • Structural basis of DEPDC1B–PTPRF versus RhoA–PTPRF competition is unknown
    • Whether DEPDC1B catalytic GAP activity toward RhoA contributes to this function was not resolved
    • Upstream signals triggering G2 accumulation of DEPDC1B are uncharacterized
  2. 2014 Medium

    In parallel, DEPDC1B was shown to possess GEF-like activity toward Rac1, promoting Rac1 membrane translocation and activating a Rac1–ERK signaling axis — revealing a second, mechanistically distinct Rho GTPase regulatory mode beyond its RhoA/PTPRF competition.

    Evidence GEF activity assays, Rac1 translocation imaging, ERK phosphorylation blotting in fibroblasts and oral cancer cells

    PMID:25091805

    Open questions at the time
    • Whether the RhoGAP domain has true catalytic GAP activity or functions as a non-canonical GEF scaffold is unresolved
    • No structural or kinetic data for the GEF activity
    • Relationship between Rac1-GEF and RhoA-competition functions unclear
  3. 2015 Medium

    Transcriptional regulation of DEPDC1B was identified: Pitx2 recruits HDAC1 to intronic binding sites in DEPDC1B to repress its expression, and the RhoGAP domain was confirmed to interact with nucleotide-bound Rac1 in vitro — establishing that DEPDC1B levels are dynamically controlled and the Rac1 interaction is direct.

    Evidence ChIP for Pitx2/HDAC1, luciferase reporters, GST pulldown with Rac1

    PMID:25704760

    Open questions at the time
    • Whether Pitx2-mediated repression is relevant outside the cardiac/craniofacial contexts studied is unknown
    • In vitro binding with Rac1 did not resolve GAP versus GEF mechanism
  4. 2019 Medium

    DEPDC1B was found to be required for myoblast proliferation independently of both RhoA and canonical Wnt/β-catenin signaling, revealing a context where its pro-proliferative function engages distinct downstream effectors.

    Evidence siRNA knockdown in mouse and human myoblasts with RhoA and β-catenin epistasis experiments

    PMID:31825138

    Open questions at the time
    • The RhoA/Wnt-independent effector in myoblasts was not identified
    • Whether Rac1 is the operative pathway in myoblasts was not tested
  5. 2020 Medium

    Multiple cancer studies converged to establish Rac1–PAK1 as the principal oncogenic effector axis of DEPDC1B: DEPDC1B–Rac1 co-immunoprecipitation was confirmed in prostate and pancreatic cancer, and Rac1 inhibition or knockdown rescued DEPDC1B-driven migration, invasion, and metastasis in vivo.

    Evidence Co-IP, Rac1-GTP inhibitor rescue, siRNA, in vivo xenograft and liver metastasis models in prostate and pancreatic cancer

    PMID:32110046 PMID:33135357

    Open questions at the time
    • Direct catalytic parameters (kcat, KM) for DEPDC1B toward Rac1 remain unmeasured
    • Whether PAK1-independent Rac1 effectors contribute is untested
    • BioID proximity data confirmed RAC1 at adhesions but did not validate specific functions (PMID:32203420)
  6. 2022 Medium

    A Rho-GTPase-independent mechanism of DEPDC1B was uncovered in melanoma: DEPDC1B stabilizes SCUBE3 by competitively binding the ubiquitin ligase subunit CDC16, preventing SCUBE3 proteasomal degradation, and is itself a direct transcriptional target of SOX10 — establishing a SOX10–DEPDC1B–SCUBE3 axis for metastasis and angiogenesis.

    Evidence Co-IP, ubiquitination assays, protein stability assays, in vivo metastasis/angiogenesis models, tissue microarray

    PMID:35088579

    Open questions at the time
    • Whether CDC16 sequestration affects other APC/C substrates beyond SCUBE3 is unknown
    • Structural basis of DEPDC1B–CDC16 interaction is uncharacterized
    • Generality of this mechanism outside melanoma is not established
  7. 2023 Medium

    DEPDC1B was shown to activate Wnt/β-catenin signaling through a defined biochemical mechanism: it recruits the deubiquitinase USP5 to β-catenin, promoting USP5-mediated deubiquitination and stabilization of β-catenin in breast cancer — resolving the mechanistic link first implied in 2014 NSCLC studies.

    Evidence Mass spectrometry interactome, reciprocal Co-IP among DEPDC1B/USP5/β-catenin, ubiquitination assays, in vivo metastasis

    PMID:37642235

    Open questions at the time
    • Whether USP5 binding requires the DEP domain or RhoGAP domain is unknown
    • Relationship between the USP5/β-catenin axis and the Rac1 axis in the same cellular context is unexplored

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis of DEPDC1B's dual Rho GTPase regulatory modes (GAP-like domain functioning as GEF), how its multiple effector pathways (Rac1, RhoA/PTPRF, β-catenin/USP5, CDC16/SCUBE3) are coordinated in space and time during the cell cycle, and whether DEPDC1B has physiological roles beyond proliferating/cancer cells.
  • No crystal or cryo-EM structure of DEPDC1B exists
  • Catalytic mechanism (GEF vs GAP vs scaffold) is biochemically unresolved
  • No mouse knockout phenotype has been reported

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 5 GO:0008092 cytoskeletal protein binding 2
Localization
GO:0005886 plasma membrane 2 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-1640170 Cell Cycle 4 R-HSA-1474244 Extracellular matrix organization 1
Partners
CDC16CTNNB1PIK3R1PTPRFRAC1SCUBE3UBE2TUSP5

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2014 DEPDC1B accumulates in G2 phase and coordinates de-adhesion events with cell-cycle progression at mitosis by functioning as an inhibitor of a RhoA-based signaling complex assembled on the focal adhesion-associated protein PTPRF (LAR). DEPDC1B competes with RhoA for binding to PTPRF, thereby promoting focal adhesion (FA) dismantling required for morphological changes preceding mitosis. Loss or gain of DEPDC1B function perturbs mitotic dynamics in zebrafish development, establishing the DEPDC1B/RhoA/PTPRF axis as a physiologically relevant de-adhesion mitotic checkpoint. Co-immunoprecipitation, competition binding assays, siRNA knockdown, live-cell imaging, zebrafish in vivo genetics, cell cycle synchronization Developmental cell High 25458010
2014 DEPDC1B activates Wnt/β-catenin signaling in non-small cell lung cancer cells; ectopic DEPDC1B expression enhances migration and invasion, and these effects are abrogated by depletion of TCF4 or LEF1, placing DEPDC1B upstream of β-catenin transcriptional output. Ectopic expression, siRNA knockdown, migration/invasion assays, TCF4/LEF1 depletion rescue experiments, reporter assays Biochemical and biophysical research communications Medium 24971537
2014 DEPDC1B functions as a guanine nucleotide exchange factor (GEF) for Rac1: its DEP+RhoGAP-like domain promotes translocation of Rac1 to the cell membrane, induces cell migration in embryonic fibroblasts and invasion in cancer cell lines, and promotes anchorage-independent growth in oral cancer cells via a DEPDC1B-Rac1-ERK1/2 signaling axis. GEF activity assays, Rac1 membrane translocation imaging, migration/invasion assays, siRNA knockdown, ERK1/2 phosphorylation western blot Journal of biomedical science Medium 25091805
2015 Pitx2, a bicoid-related homeobox transcription factor, directly represses DEPDC1B transcription by recruiting HDAC1 to consensus binding sites in the first intron of DEPDC1B, as shown by ChIP. The RhoGAP domain of DEPDC1B interacts with nucleotide-bound RAC1 in vitro, suppresses RAC1 activation, and interferes with actin polymerization induced by the GEF TRIO. DEPDC1B also interacts with signaling molecules U2af2, Erh, and Salm. Chromatin immunoprecipitation (ChIP), luciferase reporter assay, RNAi-mediated Pitx2 depletion, in vitro GST pulldown with RAC1, actin polymerization assay Experimental cell research Medium 25704760
2019 DEPDC1B is a key regulator of myoblast proliferation: it is expressed in proliferating murine and human myoblasts and decreases upon myogenic differentiation. siRNA-mediated knockdown of DEPDC1B reduces myoblast proliferation, deregulates key cell cycle regulators (cyclins, CDK, CDKi), and induces premature entry into myogenic differentiation. DEPDC1B and RhoA co-knockdown has additive effects on reducing proliferation and enhancing differentiation, suggesting DEPDC1B acts partly independently of RhoA in this context. DEPDC1B and β-catenin co-knockdown cannot rescue proliferation, indicating DEPDC1B functions independently of canonical WNT signaling in myogenesis. siRNA knockdown, RT-qPCR, immunolabelling, cell cycle analysis, myogenic differentiation assays in mouse and human myoblasts and rhabdomyosarcoma cells Cell proliferation Medium 31825138
2020 DEPDC1B promotes prostate cancer cell proliferation and EMT by directly binding Rac1 and enhancing the Rac1-PAK1 signaling pathway. The oncogenic effects of DEPDC1B are reversed by a Rac1-GTP inhibitor or Rac1 knockdown, establishing Rac1 as the required downstream effector. Co-immunoprecipitation, Rac1 activity assays, Rac1 inhibitor treatment, siRNA knockdown, migration/invasion assays, in vivo xenograft Clinical and translational medicine Medium 33135357
2020 DEPDC1B promotes pancreatic cancer cell migration and invasion through the Rac1/PAK1-LIMK1-cofilin1 signaling pathway: DEPDC1B interacts with Rac1 (by co-immunoprecipitation), and Rac1 inhibition suppresses DEPDC1B-induced migration and invasion in vitro and liver metastasis in vivo. Immunoprecipitation, western blotting, wound healing, Transwell assay, Rac1 inhibitor, in vivo liver metastasis model OncoTargets and therapy Medium 32110046
2020 DEPDC1B promotes bladder cancer progression through SHC1: knockdown of SHC1 in DEPDC1B-overexpressed bladder cancer cells abolishes the proliferative, migratory and anti-apoptotic effects of DEPDC1B, identifying SHC1 as an essential downstream mediator of DEPDC1B oncogenic signaling. siRNA/shRNA knockdown, rescue overexpression, MTT, colony formation, flow cytometry, in vivo xenograft Cell death & disease Low 33203836
2021 DEPDC1B regulates chordoma progression through UBE2T-mediated ubiquitination of BIRC5 (Survivin): Co-IP confirmed interaction between DEPDC1B and UBE2T; DEPDC1B knockdown reduces BIRC5 protein stability via the ubiquitin-proteasome pathway, and BIRC5 overexpression reverses the inhibitory effects of DEPDC1B knockdown. Co-immunoprecipitation, RNA sequencing, ubiquitination assay, rescue experiments, in vivo xenograft Cell death & disease Medium 34330893
2021 DEPDC1B promotes hepatocellular carcinoma progression via CDK1: DEPDC1B knockdown inhibits cell proliferation, migration, and colony formation and leads to G2-phase arrest; CDK1 rescue restores these effects, identifying CDK1 as a key downstream effector of DEPDC1B in HCC. GeneChip array, siRNA knockdown, MTT, colony formation, flow cytometry, Transwell assay, rescue CDK1 overexpression, in vivo xenograft Aging Low 34032605
2022 DEPDC1B promotes melanoma metastasis and angiogenesis through stabilization of secreted SCUBE3 protein: DEPDC1B competitively associates with ubiquitin ligase CDC16 to prevent CDC16-mediated ubiquitin-proteasome degradation of SCUBE3. This mechanism is independent of Rho GTPase and canonical Wnt signaling. DEPDC1B is a direct transcriptional target of SOX10, establishing a SOX10-DEPDC1B-SCUBE3 axis. Co-immunoprecipitation, ubiquitination assay, protein stability assay, gain/loss-of-function, in vivo metastasis/angiogenesis models, tissue microarray Advanced science Medium 35088579
2020 DEPDC1B promotes pancreatic ductal adenocarcinoma cell migration and invasion by activating the Akt/GSK3β/Snail signaling pathway and inducing EMT; DEPDC1B overexpression leads to Akt phosphorylation and downstream Snail upregulation as assessed by western blotting and immunofluorescence. Western blotting, immunofluorescence, shRNA knockdown, overexpression, migration/invasion assays Oncology letters Low 32934714
2023 DEPDC1B mediates deubiquitination of β-catenin via USP5 to activate Wnt/β-catenin signaling in breast cancer: Co-IP confirmed interaction among DEPDC1B, USP5, and β-catenin; DEPDC1B promotes USP5-dependent deubiquitination of β-catenin, increasing β-catenin stability and enhancing cell invasion and migration. Mass spectrometry interactome, co-immunoprecipitation, ubiquitination assay, siRNA knockdown, rescue experiments, in vivo metastasis model American journal of physiology. Cell physiology Medium 37642235
2022 DEPDC1B collaborates with GABRD to regulate esophageal squamous cell carcinoma progression: a direct protein-protein interaction between DEPDC1B and GABRD was confirmed, and GABRD knockdown partially reverses DEPDC1B-driven tumor progression potentially via PI3K/AKT/mTOR signaling. Co-immunoprecipitation, shRNA knockdown, rescue experiments, in vitro and in vivo functional assays Cancer cell international Low 35706026
2023 DEPDC1B interacts with NUP37 (nucleoporin 37) by co-immunoprecipitation, and NUP37 overexpression reverses the inhibitory effects of DEPDC1B silencing on CRC cell proliferation, migration, invasion and PI3K/AKT signaling, establishing NUP37 as a downstream effector of DEPDC1B in colorectal cancer. Co-immunoprecipitation, bioinformatics, siRNA knockdown, rescue overexpression, western blotting, in vivo xenograft Molecular medicine reports Low 37203403
2022 DEPDC1B promotes cholangiocarcinoma progression by enhancing the protein stability of CDK1; DEPDC1B knockdown decreases CDK1 protein levels through the ubiquitin-proteasome system, and CDK1 knockdown weakens the tumor-promoting effects of DEPDC1B overexpression. Gene profiling, western blotting, ubiquitin-proteasome pathway analysis, rescue CDK1 knockdown, in vivo xenograft Frontiers in oncology Low 36568241
2024 ZNF146 positively regulates DEPDC1B expression via TFDP1: ZNF146 knockdown induces G0/G1 arrest rescued by TFDP1 overexpression; TFDP1 transcriptionally activates DEPDC1B, and DEPDC1B increases the G2/M fraction and promotes tumor malignancy — effects reversed by sh-ZNF146 but rescued by DEPDC1B restoration, establishing a ZNF146/TFDP1/DEPDC1B transcriptional axis controlling cell cycle in ovarian cancer. siRNA/shRNA knockdown, rescue overexpression, flow cytometry (cell cycle), luciferase reporter assay, in vivo xenograft Reproduction Low 38614125
2023 DEPDC1B promotes ovarian cancer cell proliferation by enhancing AKT phosphorylation at Ser473; AKT inhibitors MK2206 and LY294002 suppress DEPDC1B-induced proliferation, placing DEPDC1B upstream of PI3K/AKT signaling in this cancer context. Overexpression, western blotting (pAKT Ser473), pharmacological AKT inhibition, proliferation assays Journal of Cancer Low 37056386
2022 DEPDC1B promotes hepatocellular carcinoma via KIF23: DEPDC1B knockdown reduces KIF23 expression; KIF23 overexpression reverses DEPDC1B knockdown-induced inhibition of HCC cell proliferation and migration; this axis activates the p53 signaling pathway. Co-immunoprecipitation confirmed interaction between DEPDC1B and KIF23. Co-immunoprecipitation, siRNA knockdown, rescue KIF23 overexpression, p53 pathway western blotting, proliferation/migration assays Bioengineered Low 34983303
2023 DEPDC1B enhances malignant phenotypes of multiple myeloma through upregulation of CCNB1 (Cyclin B1) while inhibiting the p53 signaling pathway; CCNB1 was identified as a co-expressed downstream target mediating DEPDC1B effects, and DEPDC1B knockdown activates the p53 pathway. siRNA/shRNA knockdown, overexpression, western blotting, flow cytometry, in vivo xenograft, co-expression analysis Tissue & cell Low 37979396
2025 EBF1 transcriptionally represses DEPDC1B in colon adenocarcinoma; EBF1 promoter hypermethylation in COAD leads to loss of EBF1 and consequent transcriptional activation of DEPDC1B, which drives cell cycle progression and EMT. Restoration of EBF1 reduces DEPDC1B expression, and DEPDC1B re-expression negates the tumor-suppressive effects of EBF1 overexpression. 5-azacytidine demethylation, RT-qPCR, siRNA/shRNA knockdown, rescue overexpression, flow cytometry, in vivo syngraft model Biochemical genetics Low 41402613
2023 DEPDC1B N-terminus binds the p85 subunit of PI3K; DEPDC1B overexpression results in decreased ligand-stimulated tyrosine phosphorylation of p85 and downregulation of pAKT1, while also positively regulating pERK, positioning DEPDC1B as a cross-regulator of AKT1 and ERK pathways downstream of Raf-1. Co-immunoprecipitation (N-terminus/p85 binding), western blotting (pERK, pAKT1), siRNA knockdown Methods in molecular biology Low 37191806
2020 Systems-level RhoGEF/RhoGAP interactome mapping by BioID identified DEPDC1B as a RhoGAP-domain protein with RAC1 in its proximity interaction network, consistent with its role as a RAC1 regulator at integrin adhesions. Proximity-dependent biotinylation (BioID), mass spectrometry Nature cell biology Low 32203420

Source papers

Stage 0 corpus · 95 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2015 The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 1118 26186194
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
2003 Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature genetics 754 14702039
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2012 Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Molecular cell 582 23246432
2018 High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies. Molecular cell 580 29395067
2015 A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface. Cell 433 26638075
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
2021 A proximity-dependent biotinylation map of a human cell. Nature 339 34079125
2016 An organelle-specific protein landscape identifies novel diseases and molecular mechanisms. Nature communications 211 27173435
2011 Toward an understanding of the protein interaction network of the human liver. Molecular systems biology 207 21988832
2018 An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations. Nature communications 201 29568061
2020 Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions. Nature cell biology 194 32203420
2020 A High-Density Human Mitochondrial Proximity Interaction Network. Cell metabolism 148 32877691
2019 Mapping the proximity interaction network of the Rho-family GTPases reveals signalling pathways and regulatory mechanisms. Nature cell biology 137 31871319
2019 The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2. Molecular cell 124 30639242
2010 Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome research 119 20923822
2011 Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. American journal of human genetics 95 21596366
2019 Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination. Frontiers in immunology 93 31866999
2012 Charting the landscape of tandem BRCT domain-mediated protein interactions. Science signaling 92 22990118
2014 DEPDC1B coordinates de-adhesion events and cell-cycle progression at mitosis. Developmental cell 76 25458010
2018 Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nature communications 73 30194290
2018 LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis. Biochimie 66 30347231
2021 Comprehensive interactome profiling of the human Hsp70 network highlights functional differentiation of J domains. Molecular cell 64 33957083
2023 BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis. Circulation 60 37781816
2014 DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/β-catenin signaling. Biochemical and biophysical research communications 60 24971537
2023 A central chaperone-like role for 14-3-3 proteins in human cells. Molecular cell 54 36931259
2022 Physical and functional interactome atlas of human receptor tyrosine kinases. EMBO reports 50 35384245
2020 The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling. Clinical and translational medicine 49 33135357
2014 A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK. Journal of biomedical science 47 25091805
2022 NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature immunology 46 36138187
2007 Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation. International journal of molecular medicine 44 17143545
2019 PLEKHA4/kramer Attenuates Dishevelled Ubiquitination to Modulate Wnt and Planar Cell Polarity Signaling. Cell reports 42 31091453
2021 Long noncoding RNA TMPO-AS1/miR-126-5p/BRCC3 axis accelerates gastric cancer progression and angiogenesis via activating PI3K/Akt/mTOR pathway. Journal of gastroenterology and hepatology 37 33295056
2023 miR-369-3p Modulates Intestinal Inflammatory Response via BRCC3/NLRP3 Inflammasome Axis. Cells 31 37681916
2021 The involvement of Parkin-dependent mitophagy in the anti-cancer activity of Ginsenoside. Journal of ginseng research 31 35509820
2020 DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1. Cell death & disease 31 33203836
2019 The BRCC3 regulated by Cdk5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson's disease models. Biochemical and biophysical research communications 30 31787240
2017 High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer. Oncology letters 30 29163701
2019 DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. Experimental cell research 29 30880030
2020 DEP Domain-Containing Protein 1B (DEPDC1B) Promotes Migration and Invasion in Pancreatic Cancer Through the Rac1/PAK1-LIMK1-Cofilin1 Signaling Pathway. OncoTargets and therapy 28 32110046
2015 BRCC3 mutations in myeloid neoplasms. Haematologica 25 26001790
2024 BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension. Circulation 24 38557054
2021 Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1. Aging 23 34032605
2016 B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. Oncology reports 23 27175567
2024 BRCC3 mediates inflammation and pyroptosis in cerebral ischemia/reperfusion injury by activating the NLRP6 inflammasome. CNS neuroscience & therapeutics 22 38544474
2021 N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective. International journal of molecular sciences 22 33916271
2019 Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). Leukemia 22 31576005
2021 BRCC3 Promotes Tumorigenesis of Bladder Cancer by Activating the NF-κB Signaling Pathway Through Targeting TRAF2. Frontiers in cell and developmental biology 20 34604222
2023 Inhibition of CD82 improves colitis by increasing NLRP3 deubiquitination by BRCC3. Cellular & molecular immunology 19 36600050
2022 DEPDC1B Promotes Melanoma Angiogenesis and Metastasis through Sequestration of Ubiquitin Ligase CDC16 to Stabilize Secreted SCUBE3. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 19 35088579
2018 Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas. Histology and histopathology 18 29297565
2024 BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway. Science advances 17 39231216
2021 BRCC3 promotes activation of the NLRP6 inflammasome following cerebral ischemia/reperfusion (I/R) injury in rats. Neuroscience letters 15 33979701
2021 DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5. Cell death & disease 15 34330893
2020 ABRO1 stabilizes the deubiquitinase BRCC3 through inhibiting its degradation mediated by the E3 ubiquitin ligase WWP2. FEBS letters 15 33107021
2019 DEPDC1B is a key regulator of myoblast proliferation in mouse and man. Cell proliferation 15 31825138
2018 Knockdown of BRCC3 exerts an anti‑tumor effect on cervical cancer in vitro. Molecular medicine reports 15 30272359
2023 A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 14 36976175
2021 Inhibition of lncRNA NEAT1 protects endothelial cells against hypoxia/reoxygenation‑induced NLRP3 inflammasome activation by targeting the miR‑204/BRCC3 axis. Molecular medicine reports 14 34850961
2020 DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway. Oncology letters 14 32934714
2023 DEPDC1B-mediated USP5 deubiquitination of β-catenin promotes breast cancer metastasis by activating the wnt/β-catenin pathway. American journal of physiology. Cell physiology 12 37642235
2015 Identification of the GTPase-activating protein DEP domain containing 1B (DEPDC1B) as a transcriptional target of Pitx2. Experimental cell research 12 25704760
2023 Vitamin D3 attenuates SARS-CoV-2 nucleocapsid protein-caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway in vitro and in vivo. MedComm 10 37361896
2016 In Silico Approach for SAR Analysis of the Predicted Model of DEPDC1B: A Novel Target for Oral Cancer. Advances in bioinformatics 10 27034663
2023 DEPDC1B is involved in the proliferation, metastasis, cell cycle arrest and apoptosis of colon cancer cells by regulating NUP37. Molecular medicine reports 9 37203403
2022 DEPDC1B collaborates with GABRD to regulate ESCC progression. Cancer cell international 9 35706026
2022 DEPDC1B promotes colorectal cancer via facilitating cell proliferation and migration while inhibiting apoptosis. Cell cycle (Georgetown, Tex.) 9 36016512
2020 Knockdown of DEPDC1B inhibits the development of glioblastoma. Cancer cell international 9 32684847
2024 The deubiquitinase BRCC3 increases the stability of ZEB1 and promotes the proliferation and metastasis of triple-negative breast cancer cells. Acta biochimica et biophysica Sinica 8 38449391
2024 Deletion of BRCC3 ameliorates airway inflammation in asthma by inhibiting the activation of NLRP3 inflammasome. International immunopharmacology 8 39642564
2024 ZNF146 regulates cell cycle progression via TFDP1 and DEPDC1B in ovarian cancer cells. Reproduction (Cambridge, England) 7 38614125
2022 DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23). Bioengineered 7 34983303
2014 Arrested detachment: a DEPDC1B-mediated de-adhesion mitotic checkpoint. Developmental cell 7 25458006
2023 UCA1 executes an oncogenic role in pancreatic cancer by regulating miR-582-5p/BRCC3. Frontiers in oncology 6 37564930
2022 The TRIM14-USP14-BRCC3 complex epigenetically regulates inflammation through inhibiting OPTN-mediated autophagic degradation of KDM4D. Autophagy 5 35311471
2023 Platycodin D inhibits glioblastoma cell proliferation, migration, and invasion by regulating DEPDC1B-mediated epithelial-to-mesenchymal transition. European journal of pharmacology 4 37742812
2023 Circ_0005276 Promotes Prostate Cancer Progression Through the Crosstalk of miR-128-3p/DEPDC1B Axis. Biochemical genetics 3 36913076
2023 Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer. Journal of Cancer 3 37056386
2023 Identification of BRCC3 and BRCA1 as Regulators of TAZ Stability and Activity. Cells 3 37887275
2025 DEPDC1B, CDCA2, APOBEC3B, and TYMS are potential hub genes and therapeutic targets for diagnosing dialysis patients with heart failure. Frontiers in cardiovascular medicine 2 39844908
2025 BRCC3 aggravates pulpitis by activating the NF-κB signaling pathway in dental pulp cells. Biochimica et biophysica acta. Molecular basis of disease 2 39880291
2020 Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B) monoclonal antibodies. The Journal of veterinary medical science 2 32147621
2024 Deubiquitinase BRCC3 promotes the migration, invasion and EMT progression of colon adenocarcinoma by stabilizing MET expression. Genes & genomics 1 38470543
2024 BRCC3 -Associated Syndromic Moyamoya Angiopathy Diagnosed Through Clinical RNA Sequencing. Clinical genetics 1 39552268
2023 XTP1 facilitates the growth and development of gastric cancer by activating CDK6. Annals of translational medicine 1 36819538
2023 DEPDC1B enhances malignant phenotypes of multiple myeloma through upregulating CCNB1 and inhibiting p53 signaling pathway. Tissue & cell 1 37979396
2022 DEPDC1B promotes development of cholangiocarcinoma through enhancing the stability of CDK1 and regulating malignant phenotypes. Frontiers in oncology 1 36568241
2026 Paeonol alleviates pulmonary arterial hypertension by activation of BRCC3. Phytomedicine : international journal of phytotherapy and phytopharmacology 0 41638058
2025 Transcription Activation of DEPDC1B Upon EBF1 Loss Contributes to Cell Cycle Progression and Epithelial-Mesenchymal Transition in Colon Adenocarcinoma. Biochemical genetics 0 41402613
2024 Loss of Brcc3 in Zebrafish Embryos Increases Their Susceptibility to DNA Damage Stress. International journal of molecular sciences 0 39596176
2023 Illuminating DEPDC1B in Multi-pronged Regulation of Tumor Progression. Methods in molecular biology (Clifton, N.J.) 0 37191806
2022 Identification and Verification of the Ability of Cdk5 to Phosphorylate Deubiquitinating Enzyme BRCC3 In Vitro. Bulletin of experimental biology and medicine 0 35503584